Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,875.30 | 60.00 | 0.68% |
CAC 40 | 7,766.21 | 41.96 | -0.54% |
DAX 40 | 24,060.29 | 100.35 | -0.42% |
Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
FTSE 100 | 8,938.32 | 59.74 | -0.66% |
HKSE | 24,590.12 | 386.80 | 1.60% |
NASDAQ | 20,677.80 | 37.47 | 0.18% |
Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
S&P 500 | 6,243.76 | 24.80 | -0.40% |
S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
SSE Composite Index | 3,505.00 | 14.65 | -0.42% |